CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2012	Jun. 30, 2011	Jun. 30, 2012	Jun. 30, 2011
Revenue
Housing	$ 0	$ 0	$ 142,200	$ 0
Commercial rental	0	0	0	0
Tissue array products	112,407	123,419	212,317	237,230
Total revenue	112,407	123,419	354,517	237,230
Cost of Sales
Housing	0	0	123,306	0
Commercial rental	16,414	17,125	32,880	31,752
Tissue array products	65,120	102,176	144,434	189,324
Total cost of sales	81,534	119,301	300,620	221,076
Gross Profit	30,873	4,118	53,897	16,154
Operating Expenses:
Salaries and wages	50,316	41,093	102,560	81,576
Depreciation and amortization	36,561	36,721	75,008	72,993
Professional fees	19,026	10,783	37,735	57,108
Operating tax expenses	10,985	54	27,214	125
Selling and distribution expenses	1,374	3,786	2,753	10,211
Other general and administrative expenses	24,541	25,352	54,854	51,637
Bad debt expense	0	23,226	0	68,830
Total Operating Expenses	142,803	141,015	300,124	342,480
Loss from Operations	(111,930)	(136,897)	(246,227)	(326,326)
Other Income
Net interest expense	(46,132)	(1,085)	(92,122)	(598)
Other (expense) income, net	3,496	(14)	(22,561)	229
Total Other Expense, Net	(42,636)	(1,099)	(114,683)	(369)
Loss before Income Taxes	(154,566)	(137,996)	(360,910)	(326,695)
Income Tax Expense	(162)	0	(162)	0
Net loss	(154,728)	(137,996)	(361,072)	(326,695)
Net loss attributable to the noncontrolling interest	(29,860)	(28,160)	(68,325)	(53,169)
Net loss attributable to CYBRDI, INC. AND SUBSIDIARIES	$ (124,868)	$ (109,836)	$ (292,747)	$ (273,526)
Net Loss Per Common Share
Basic and Diluted	$ 0.00	$ 0.00	$ 0.00	$ 0.00
Weighted Average Number of Shares Outstanding
Basic and Diluted	120,225,323	65,756,567	120,225,323	65,756,567